|Bid||0.00 x 28400|
|Ask||0.00 x 2100|
|Day's range||93.49 - 95.62|
|52-week range||91.51 - 123.90|
|PE ratio (TTM)||11.14|
|Forward dividend & yield||2.80 (2.93%)|
|1y target est||N/A|
Bayer Aktiengesellschaft / Preliminary announcement on the disclosure offinancial statements21.02.2018 / 08:00Preliminary announcement of the publication of financial reports accordingto Articles 114, 115, 117 of the WpHG [the German Securities Act]transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. ...
Bayer and Monsanto (NYSE: MON) today announced that the Committee on Foreign Investment in the United States (“CFIUS”) has completed its review of the proposed merger, and has concluded that there are no unresolved national security concerns with respect to the transaction. The acquisition is subject to customary closing conditions, including receipt of required regulatory approvals. Bayer and Monsanto will continue to cooperate with the authorities in order to complete the transaction in early 2018.
READING, U.K.--(BUSINESSWIRE)-- Bayer’s data shows Xarelto ® ▼ (rivaroxaban) significantly lowers the combined risk of stroke, cardiovascular death and heart attack in patients with chronic coronary or ...